\
&
Contact us
\
&
Contact us
It supports all stages of innovation from R&D on the scientific underpinnings of breakthrough technologies, to validation and demonstration of breakthrough technologies and innovations to meet real world needs, to the development and scaling up of start-ups and small and medium-sized enterprises (SMEs).
The funding and support consists of three main funding schemes:
In each funding scheme, the direct financial support to innovators is augmented with access to a range of Business Acceleration Services. The three main EIC instruments offer both bottom-up calls and calls with predefined thematic priorities (challenges). In addition to these instruments there are the EIC Prizes, which reward innovative solutions offered by companies/organisations for pre-defined societal challenges or specific target audiences, such as women innovators, innovative cities, public or private procurers or social innovation.
magali.parent@vlaio.be
+32 2 432 42 42
Ria.debreucker@vlaio.be
+32 2 553 13 77
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Digital, Industry & Space Climate, Energy, Mobility EIC EIT
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
